The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.
HTAs: Adjusting Overall Survival for Treatment Switch
We continue our series of blogs covering the expert presentations from the EAST User Group Meeting. Consultant Claire Watkins of Clarostat provided a different statistical focus, moving the discussion to a later point in the product lifecycle and the area of Health Technology Assessment. Her presentation, which tackled the topic of Adjusting Overall Survival for Treatment switch, shared the recommendations of a cross-institutional statistical working group ( Sub team of the PSI HTA Special Interest Group).
Statisticians have crucial role to play in the area of health economics and health technology assessments since payers like regulators require submissions which are robust and evidence based. However there are key differences in the perspectives of regulators and HTA agencies posing different challenges for statisticians involved in such submissions.